Revitalist and Pharmather to collaborate on novel and standardized treatment protocols for for ketamine-based psychotherapy.
Revitalist and Pharmather to collaborate on novel and standardized treatment protocols for for ketamine-based psychotherapy.
Red Light Holland reports quarterly revenue growth of 28% and gross profit growth of 48% for Q3 of fiscal 2022. Strong cash position of CAD$27.3 million.
Mydecine prepares to submit its IND and application for Breakthrough Therapy Status for smoking cessation after successful meeting with FDA.
Novamind reports 32% q-o-q revenue growth, up to CAD $2.45 million in its latest quarter. Cash balance of ~CAD$8 million including post-period financing.
Enveric Biosciences announces the filing of its 10th patent application for its tryptamine-based molecules.
Revitalist obtains regulatory approval for its clinics to host human clinical trials for psychedelics-based therapies.
Compass quarterly and full-year loss increases marginally. End-of-year cash position of $273.2 million. Strong results in Phase IIb study.
Pasiethea Therapeutics plans to offer three new clinics offering both ketamine-based and "repeated transcranial magnetic stmulation" treatments (rTMS).
Optimi Health announces the launch of six nootropic supplements derived from functional mushrooms.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now